BRCA2 and Familial prostate cancer: CGP of cfDNA from 7,707 unique men with advanced prostate cancer was available to assess the presence of mutations in BRCA1 and/or BRCA2. The median age for the total cohort was 72 years (interquartile range 65-78 years).